CN116549378A - 一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法 - Google Patents
一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法 Download PDFInfo
- Publication number
- CN116549378A CN116549378A CN202310591567.XA CN202310591567A CN116549378A CN 116549378 A CN116549378 A CN 116549378A CN 202310591567 A CN202310591567 A CN 202310591567A CN 116549378 A CN116549378 A CN 116549378A
- Authority
- CN
- China
- Prior art keywords
- saponin
- pulsatilla
- gel
- carbomer
- rectum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 88
- 229930182490 saponin Natural products 0.000 title claims abstract description 88
- 150000007949 saponins Chemical class 0.000 title claims abstract description 88
- 241000123887 Pulsatilla chinensis Species 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 58
- 210000004877 mucosa Anatomy 0.000 title abstract description 20
- 239000000829 suppository Substances 0.000 claims abstract description 62
- 210000000664 rectum Anatomy 0.000 claims abstract description 44
- 239000011159 matrix material Substances 0.000 claims abstract description 37
- 229940041666 rectal gel Drugs 0.000 claims abstract description 12
- 239000006215 rectal suppository Substances 0.000 claims abstract description 7
- 229940100618 rectal suppository Drugs 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 92
- OUHBKBTZUPLIIA-OTEDBJMHSA-N [(2s,3r,4s,5s,6r)-6-[[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (1r,3as,5ar,5br,7ar,8r,9s,11ar,11br,13ar,13br)-9-[(2s,3r,4s,5s)-4,5-dihydroxy- Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC(=O)[C@@]34[C@H]([C@@H](CC3)C(C)=C)[C@@H]3[C@@]([C@]5(C)CC[C@H]6[C@](C)(CO)[C@@H](O[C@H]7[C@@H]([C@@H](O)[C@@H](O)CO7)O[C@H]7[C@@H]([C@H](O)[C@@H](O)[C@H](C)O7)O)CC[C@]6(C)[C@H]5CC3)(C)CC4)O2)O)[C@H](O)[C@H]1O OUHBKBTZUPLIIA-OTEDBJMHSA-N 0.000 claims description 52
- 235000011187 glycerol Nutrition 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 35
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 28
- 239000000194 fatty acid Substances 0.000 claims description 28
- 229930195729 fatty acid Natural products 0.000 claims description 28
- 238000010438 heat treatment Methods 0.000 claims description 27
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 26
- 208000033626 Renal failure acute Diseases 0.000 claims description 25
- 201000011040 acute kidney failure Diseases 0.000 claims description 25
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- 125000005456 glyceride group Chemical group 0.000 claims description 18
- 238000001816 cooling Methods 0.000 claims description 17
- 238000002844 melting Methods 0.000 claims description 16
- 230000008018 melting Effects 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 14
- 229940057995 liquid paraffin Drugs 0.000 claims description 11
- 238000007790 scraping Methods 0.000 claims description 11
- 241000206469 Pulsatilla Species 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000003906 humectant Substances 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 229930184121 pulsatilla saponin Natural products 0.000 claims description 5
- 241001635598 Enicostema Species 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 229940085237 carbomer-980 Drugs 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 230000009471 action Effects 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 73
- 235000017709 saponins Nutrition 0.000 description 68
- 239000000843 powder Substances 0.000 description 31
- 239000000203 mixture Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 210000002700 urine Anatomy 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 13
- 229930182566 Gentamicin Natural products 0.000 description 13
- 229960002518 gentamicin Drugs 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 11
- 229960004316 cisplatin Drugs 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 101150092493 CREA gene Proteins 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000012154 double-distilled water Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241001083548 Anemone Species 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000012998 acute renal failure Diseases 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 101000733256 Rattus norvegicus Tumor suppressor ARF Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 101710102803 Tumor suppressor ARF Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229940105442 cisplatin injection Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000009806 pulsatillae Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical class CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310591567.XA CN116549378A (zh) | 2018-01-08 | 2018-01-08 | 一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310591567.XA CN116549378A (zh) | 2018-01-08 | 2018-01-08 | 一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法 |
CN201810014548.XA CN108143710A (zh) | 2018-01-08 | 2018-01-08 | 一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810014548.XA Division CN108143710A (zh) | 2018-01-08 | 2018-01-08 | 一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116549378A true CN116549378A (zh) | 2023-08-08 |
Family
ID=62461156
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310591567.XA Pending CN116549378A (zh) | 2018-01-08 | 2018-01-08 | 一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法 |
CN201810014548.XA Pending CN108143710A (zh) | 2018-01-08 | 2018-01-08 | 一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810014548.XA Pending CN108143710A (zh) | 2018-01-08 | 2018-01-08 | 一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN116549378A (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111084779A (zh) * | 2018-10-23 | 2020-05-01 | 广西英路维特药物有限公司 | 白头翁皂苷b4的新用途 |
CN109432110A (zh) * | 2018-12-28 | 2019-03-08 | 天津凯茵科技有限公司 | 一种硝酸咪康唑妇科用复方组合物 |
CN111249289A (zh) * | 2020-02-14 | 2020-06-09 | 广西英路维特药物有限公司 | 一种消炎和/或抗过敏的口腔护理产品或药品 |
EP4115888A4 (en) * | 2020-03-03 | 2023-07-19 | Qi Liu | MEDICAL USE OF ANEMOSIDE B4 FOR THE TREATMENT OF BOUTH Ulcers |
CN112315934B (zh) * | 2020-10-27 | 2022-11-11 | 广西馨海药业科技有限公司 | 白头翁皂苷b4肠溶片的制备工艺 |
CN112370461B (zh) * | 2020-12-04 | 2023-05-16 | 广西馨海药业科技有限公司 | 白头翁皂苷b4在制备治疗痔疮的药物中的用途 |
CN112569190B (zh) * | 2020-12-31 | 2022-03-01 | 苏州大学 | 一种白头翁皂苷b4的口服给药制剂及其制备方法 |
CN116196270A (zh) * | 2023-05-05 | 2023-06-02 | 江西中医药大学 | 一种用于治疗溃疡性结肠炎的原位凝胶制剂及制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102213617B1 (ko) * | 2014-08-12 | 2021-02-05 | 주식회사 엘지생활건강 | 풀키네노시드 b4를 포함하는 피부 미백 또는 항염증용 화장료 또는 약학 조성물 |
CN104288167B (zh) * | 2014-10-29 | 2017-08-25 | 马应龙药业集团股份有限公司 | 一种治疗痔疮的七叶皂苷钠制剂及其制备方法 |
CN105213410B (zh) * | 2015-10-20 | 2018-12-18 | 刘琦 | 白头翁皂苷b4作为免疫调节剂在治疗急性炎症药物中的应用 |
CN107137413B (zh) * | 2017-06-21 | 2020-07-14 | 苏州大学 | 白头翁皂苷b4在制备治疗疼痛的药物中的应用 |
CN107158056A (zh) * | 2017-07-11 | 2017-09-15 | 十堰市太和医院 | 一种柴胡栓剂的制备方法 |
-
2018
- 2018-01-08 CN CN202310591567.XA patent/CN116549378A/zh active Pending
- 2018-01-08 CN CN201810014548.XA patent/CN108143710A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN108143710A (zh) | 2018-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116549378A (zh) | 一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法 | |
AU2014360040B2 (en) | Desmodium styracifolium (Osb.) Merr. flavonoids capsule, method of preparing same, and application thereof | |
CN110833595B (zh) | 一种用于治疗痛风的中药组合物及其制备方法 | |
EP3650009A1 (en) | Preparation of pulsatilla saponin b4 for injection | |
US11253471B2 (en) | Rectal mucosal administration preparation of Pulsatilla chinensis saponin B4 and preparation method therefor | |
EP2172206A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
CN108853167A (zh) | 一种含有壳聚糖的痔疮组合物、制备方法及其应用 | |
CN109528719B (zh) | 长春西汀在制备预防和/或治疗急进高原导致的高原病的药物中的应用 | |
CN1857400A (zh) | 夏枯草薄膜衣片及其制备方法 | |
CN100367938C (zh) | 四黄泻火滴丸及其制备方法 | |
CN1827128A (zh) | 一种双黄连阴道用药物及其制备方法 | |
RU2778314C2 (ru) | Препарат сапонина b4 из pulsatilla chinensis (bge.) regel для введения через слизистую оболочку прямой кишки и способ его изготовления | |
CN101249129B (zh) | 一种治疗糖尿病的中药提取物组合物及其医药用途 | |
CN100367934C (zh) | 养阴清肺滴丸 | |
CN1111412C (zh) | 三七总皂甙软胶囊及其制备工艺 | |
CN100358562C (zh) | 川贝枇杷滴丸及其制备方法 | |
CN111821295A (zh) | (5r)-5-羟基雷公藤内酯醇在制备治疗和/或预防皮肤炎症药物中的应用 | |
CN103768203A (zh) | 清开灵冻干片及其制备方法 | |
CN100358500C (zh) | 灯盏地龙滴丸 | |
CN116139164B (zh) | 一种源于麻杏石甘汤具有解热抗炎作用的超分子水凝胶 | |
CN111686085B (zh) | 一种咽喉清喉制剂的制备方法 | |
CN101224244A (zh) | 一种小儿清热栓剂及其制备方法 | |
CN118141852A (zh) | 一种桑提取物温敏凝胶及其制备方法与应用 | |
US20110071225A1 (en) | Method for obtaining a sequoyitol-containing extract from genus nephrolepis and uses thereof | |
CN111053781A (zh) | 连翘酯苷a的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240409 Address after: 545000 first floor of plant 2, science and technology incubation project, Luowei industrial concentration area, No. 7, putaoshan Road, Liuzhou City, Guangxi Zhuang Autonomous Region Applicant after: Guangxi Xinhai Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: 100102 Room 302, unit 2, building 5, courtyard 6, Guangze Road, Wangjing, Chaoyang District, Beijing Applicant before: Liu Qi Country or region before: China |
|
TA01 | Transfer of patent application right |